A US medical device company developing technologies to treat ischaemic stroke has raised US$10.5m to fund therapy device.
RapidPulse plans to use the proceeds to further advance its Cyclic Aspiration System for ischaemic stroke through expanded clinical evaluation, which in turn will further the development of its platform of new catheters and aspiration pump.
The technology was created to treat ischaemic stroke patients by using a novel aspiration pump to suction out blood-blocking clots that form in the arteries leading to the brain.
The Miami-based company is also developing its own line of catheters designed to be used in tandem with the pump.
The funding round led by Syntheon and Santé Ventures will bring the company’s cumulative financing to over US$25m, allowing it to move towards FDA approval.
“RapidPulse has built an excellent team and taken great strides in developing our technology and system architecture,” said Sean McBrayer, CEO of RapidPulse as well as CEO of Syntheon.
“We’ve had three seminal patents issued to protect our intellectual property and we’ve received excellent feedback from some of the leading ischaemic stroke physicians.
“In addition, our early clinical results have been outstanding. Initial testing of our technology has shown first pass clot removal of up to 69 per cent of the time, a dramatic improvement over standard aspiration.”
He continued: “What makes RapidPulse different is the unique method of delivering precise, cyclic aspiration. If you’ve ever placed a vacuum hose close to an object and then turned on the power, you may have noticed there’s a quick burst of energy that pulls the object to the vacuum hose. But today’s aspiration systems get that effect just once when the clinician first activates the pump.
“Significant amounts of engineering analysis and design went into perfecting the RapidPulse concept, so the precise cyclic aspiration device delivers orders of magnitude more energy against the clot safely. We have three issued patents on this already with more to come.”
According to the company, doctors reported that they were able to remove a clot in less than 20 seconds, compared with the three to five minutes doctors often need to wait to see if their static aspiration system was successful in capturing the clot.
“When ‘time is brain’, that’s a meaningful difference,” McBrayer added.
Dennis McWilliams, partner at Santé Ventures, said: “Stroke is the second leading cause of death and the third leading cause of disability worldwide.
“This investment will help RapidPulse expand its clinical results and move towards regulatory approval in the US. The RapidPulse system promises to be a disruptive platform in neurovascular, and it has the clear potential to improve timely first-pass clot removal, thereby significantly improving patient outcomes for ischemic stroke patients.
“This financing will help RapidPulse build a leading position in the emerging field of cyclic aspiration for the treatment of ischaemic stroke.”
The goal for RapidPulse is to bring its technology to market so that patients who experienced an acute ischaemic stroke can have better health outcomes.
- News4 weeks ago
Meet the case manager: Jennifer Whittall
- News2 weeks ago
Your NR Headlines: Wednesday 14 February
- News3 weeks ago
Your NR headlines: Tuesday 6th February
- Brain injury case management6 days ago
Growing case management business expands even further
- Dementia news4 weeks ago
Study reveals significant racial and ethnic disparities in dementia care
- News2 weeks ago
Your NR Headlines: Thursday 8 February
- Opinion3 weeks ago
Is 2024 the year football finally takes the lead on addressing brain threat?
- Community neuro rehab2 weeks ago
Neurological speech and language therapy